CStone Pharmaceuticals (FRA:PH4) Moat Score: 3/10 (As of Jun. 25, 2026)


FRA:PH4 CStone Pharmaceuticals FRA:PH4
56 GF Score
Price €0.52
GF Value €0.13
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals Moat Score?

CStone Pharmaceuticals FRA:PH4 -2.47% 56 Moat Score is 3 as of Jun. 25, 2026. GuruFocus rates FRA:PH4 with a GF Score™ of 56/100 and a GF Value™ of €0.13 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,405 Biotechnology companies, CStone Pharmaceuticals ranks better than 75.52% on this metric.

CStone Pharmaceuticals has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

CStone Pharmaceuticals has No Moat: CStone Pharmaceuticals operates in a competitive pharmaceutical industry with limited market share and high R&D costs. While it has some intellectual property, the lack of significant regulatory barriers or strong brand loyalty results in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes CStone Pharmaceuticals might have No Moat - Very weak/transient advantages.

CStone Pharmaceuticals  (FRA:PH4) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

CStone Pharmaceuticals Moat Score Related Terms

FRA:PH4 vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, CStone Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CStone Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where CStone Pharmaceuticals's Moat Score falls into.


FRA:PH4
56GF Score
CStone Pharmaceuticals FRA:PH4
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
CStone Pharmaceuticals (FRA:PH4) has a Moat Score of 3 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, CStone Pharmaceuticals ranks #344 out of 1405 companies in the Biotechnology industry, placing it in the top 24.5%.
Is CStone Pharmaceuticals' Moat Score too high?
CStone Pharmaceuticals' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. CStone Pharmaceuticals' value of 3 is 50% above this industry median. Based on the distribution chart, CStone Pharmaceuticals ranks #344 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CStone Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CStone Pharmaceuticals ranks #344 out of 1405 companies for Moat Score. This places CStone Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. CStone Pharmaceuticals' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CStone Pharmaceuticals's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CStone Pharmaceuticals's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (FRA:PH4) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.52 — trading 301.4% above its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. CStone Pharmaceuticals' overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For CStone Pharmaceuticals (FRA:PH4), the current Moat Score is 3 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CStone Pharmaceuticals (FRA:PH4) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of €0.52 is trading 301.4% above its estimated GF Value™ of €0.13. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:PH4:

  • Moat Score: 3
  • GF Value™: €0.13 vs. price of €0.52 (301.4% above fair value)
  • GF Score™: 56/100 with 7 warning signs
  • Industry Position: 50% above the Biotechnology median (#344 of 1405)

No single metric tells the full story. See the FRA:PH4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
56GF Score

Get the complete analysis for FRA:PH4

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.52
Price
€0.13
GF Value